DUBLIN–(BUSINESS WIRE)–The “Analgesics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Amid the COVID-19 crisis, the global market for Analgesics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$59.2 Billion by 2026, growing at a CAGR of 4.7% over the analysis period.
Prescription, one of the segments analyzed in the report, is projected to grow at a 4.4% CAGR to reach US$37.7 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the OTC segment is readjusted to a revised 5.1% CAGR for the next 7-year period. This segment currently accounts for a 38.2% share of the global Analgesics market.
The U.S. Market is Estimated at $15.2 Billion in 2021, While China is Forecast to Reach $8.2 Billion by 2026
The Analgesics market in the U.S. is estimated at US$15.2 Billion in the year 2021. The country currently accounts for a 32.76% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$8.2 Billion in the year 2026 trailing a CAGR of 6.5% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR while Rest of European market (as defined in the study) will reach US$8.8 Billion by the close of the analysis period.
Opioids Segment to Reach $18.4 Billion by 2026
Opioid analgesic drugs represent the gold standard in pain relieving treatment of critically ill patients across disease segments, including COVID-19. Fentanyl, morphine, and hydromorphone are among the most commonly used IV opioid analgesic drugs in the ICU settings for COVID as well as non-COVID patients. Global Opioids segment is estimated at US$14.9 Billion in 2020, and is projected to reach US$18.4 Billion by 2026 reflecting a compounded annual growth rate of 3.7% over the analysis period. United States constitutes the largest regional market for Opioids segment, accounting for 29.9% of the global sales in 2020. China is poised to register the fastest compounded annual growth rate of 5.2% over the analysis period, to reach US$2.6 Billion by 2026.
Select Competitors (Total 146 Featured) –
- Amneal Pharmaceuticals Inc
- Apotex Inc
- AstraZeneca Plc
- Aurobindo Pharma Limited
- Bausch Health Companies Inc.
- Bayer AG
- Cipla Limited
- Eli Lilly and Company
- Endo International plc
- F. Hoffmann-La Roche AG
- Fresenius Kabi AG
- GlaxoSmithKline PLC
- Hikma Pharmaceuticals PLC
- Iroko Pharmaceuticals, LLC
- Johnson & Johnson
- Lupin Limited
- Novartis AG
- Reckitt Benckiser Group plc
- Sanofi S.A.
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Analgesics – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- A Prelude to Analgesics
- Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
- Key Segments
- Opioid Analgesics
- Non-Opioid Analgesics
- NSAIDs
- Topical NSAIDs
- Others
- Acetaminophen
- Adjuvant Analgesics
- Impact of COVID-19 on Analgesics
- NSAIDs
- NSAIDs Tend to Decrease Effectiveness of COVID-19 Vaccines, States a Yale University Study
- Opioid
- Acetaminophen
- Global Analgesics Market to Witness Rapid Growth
- Drugs Indicated for Pain Management
- The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
- Non-Opioids: Fastest Growing Category
- Competition
- Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Growing Aging Population & Increasing Burden of Chronic Diseases Spurs
- Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
- Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
- Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
- Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
- Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
- Number of New Cancer Cases and Deaths (in Million) by Region for 2018
- Advancements in Design and Delivery of Analgesic Drugs
- Development of Safer Opioids with More Safer Profiles
- Drug Pipeline with Efficacious Drugs
- OTC Analgesics Market to Witness Fastest Growth
- Topical Analgesics Market Holds Significant Share
- Combination Therapies Gain Prominence
- A Few Novel Analgesic Products under Development
- E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
- Neuropathic Pain Management: Market with High Potential
- Migraine Market: A Core Vertical in CNS Pain Management
- Migraine Care: Select Patent Expiries (2013-2015)
- Reyvow, Eli Lilly’s Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
- Three New Migraine Drugs Obtain FDA Approval
- Eli Lilly’s Emgality Receives FDA Approval
- Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/iejhja
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900